Bexorg, Inc., the pioneer of the first integrated AI and whole-human brain platform dedicated to transforming central nervous system (CNS) drug discovery and development, announced the successful completion of a $23 million Series A financing, spearheaded by Engine Ventures and supported by new investors Connecticut Innovations and E1 Ventures, as well as existing investors Amplify Partners and Starbloom Capital, bringing its total funding raised to $42.5 million.

These proceeds are slated to expand and optimize the company's AI engine, which is trained on clinically predictive whole-human brain data, and to advance CNS discovery and development programs through partnerships and internal assets, directly addressing the industry's pervasive CNS clinical trial failure rate that exceeds 95% due to the inadequacy of traditional cellular and animal models.

Bexorg’s groundbreaking approach generates comprehensive human datasets from wet-lab experimentation on living systems of diseased and non-diseased whole human brains, restoring specific molecular activities in donated postmortem brains for research purposes while honoring the gift by not restoring higher-level functions. This high-fidelity data feeds directly into proprietary AI models, enabling the generation of novel targets, biomarkers, and reliable go/no-go decisions with unprecedented accuracy, thereby unlocking new biology and opportunities in a disease area affecting over 70 million people with conditions like Alzheimer's, Parkinson's, and multiple sclerosis.

Founded in 2021 by Drs. Zvonimir Vrselja and Nenad Sestan at Yale University, following foundational research published in Nature in 2019, Bexorg has rapidly built one of the world’s largest repositories of human CNS data, now spanning hundreds of whole-brain experiments, and has secured key collaborations, including one with the University of Oxford and another with Biohaven Ltd., to advance preclinical development. The company is currently training foundation models on petabyte-scale human brain molecular data, establishing the first AI system grounded in experimentally measured human neurobiology, a transformative approach that investors believe will shorten discovery timelines and dramatically improve clinical trial success rates for critical CNS therapies.